JPRN-jRCTs031230604招募中2 期
A single-arm clinical study of the efficacy and safety of sclerotherapy with polydocanol for venous malformations and macrocystic lymphatic malformations
Mori Hiroki0 个研究点目标入组 25 人开始时间: 2024年1月30日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •1) Patients with venous malformation or cystic lymphatic malformation lesions that are considered difficult to resect (resection may result in functional impairment or loss of cosmetic appearance that interferes with daily life) and for which sclerotherapy is considered the first choice of treatment
- •2) Patients with measurable lesions (venous malformation or cystic lymphatic malformation) measuring at least 20 mm in length on MRI or CT in the extremities or 10 mm in length in the head and neck
- •3) Patients for whom written consent has been obtained from the patient or a surrogate (if the patient is under 18 years of age at the time consent is obtained)
排除标准
- •1) Patients with deep vein thrombosis or a history of thrombosis
- •2) Patients with arterial blood circulation problems (including those with atherosclerosis or diabetic microangiopathy)
- •3) Patients with difficulty walking
- •4) Patients with multiple organ damage or disseminated intravascular coagulation syndrome (DIC)
- •5) Patients taking oral contraceptives
- •6) Patients taking anticoagulants or antiplatelet agents
- •7) Patients with cardiac dysfunction of NYHA Classification II or higher
- •8) Patients in shock or pre-shock
- •9) Patients with a history of allergy to polidocanol or angiographic contrast media
- •10) Patients with bronchial asthma
- •11) Pregnant women, women who are pregnant or may become pregnant, and lactating women
- •12) Patients with inflammation or ulceration in and around the site of administration
- •13) Patients with or with a history of stroke or transient ischemic attack due to anomalous embolism via foramen ovale
- •14) Patients with hepatic dysfunction graded C (10-15 points)in the Child-Pugh classification
- •15)Patients with renal dysfunction with an estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73 m2
- •16) Patients who are taking or have taken drugs that may affect the resolution of lesions (propranolol, Kampo [Kamishoyosan, Ginsen Yoeito, Ketsuyu Kashuyu, Hoki Kenchu-to], Sirolimus). (However, Chinese herbal medicines may be included if they were withdrawn at least 2 weeks prior to the start of administration of the investigational drug.
- •17) Patients who received sclerotherapy within 6 months prior to obtaining consent
- •18) Patients participating in other clinical trials or clinical studies within 4 weeks prior to obtaining consent
- •19) Patients who are deemed ineligible for participation in this study by the principal investigator (subinvestigator)
研究者
相似试验
招募中
2 期
Efficacy and safety of buccal administration of midazolam as premedication in dental treatment under general anesthesia in pediatric patientsJPRN-jRCTs031230610Ito Takaya50
招募中
4 期
Evaluation study of ferric carboxymaltose injection in hemodialysis patientsIron deficiency anemiaJPRN-jRCTs051230025Araki Shin-ichi30
招募中
2 期
Exploratory study of every other day dosing of 40 mg of Relugolixendometriosis or uterine fibroidsD004715 or D007889JPRN-jRCTs031220707Izumi Gentaro30
尚未招募
3 期
To Study the effect of Triphala Churna with Gudh for Constipation in Pregnancy.CTRI/2023/04/051966Dr Vrushali Rameshwar Tikar
尚未招募
2 期
To study the effect of ayurvedic formulation in Bed wetting.CTRI/2024/04/066572Dr Mayuri Nemade